KalVista Pharmaceuticals (KALV) Insider Trading & Ownership → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free KALV Stock Alerts $11.86 +0.79 (+7.14%) (As of 03/28/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.81 MNumber OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$2.65 M Get KALV Insider Trade Alerts Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KALV Insider Buying and Selling by Quarter Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. KalVista Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/20/2024Benjamin L PalleikoCFOSell22,802$14.11$321,736.22 2/20/2024Edward P FeenerInsiderSell28,288$14.07$398,012.16 2/20/2024Thomas Andrew CrockettCEOSell24,888$14.11$351,169.68 2/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy29,747$14.70$437,280.90 2/6/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,474$14.74$65,946.76 1/29/2024Venrock Healthcare Capital ParMajor ShareholderBuy80,600$14.22$1,146,132.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 1/26/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,174$12.98$54,178.52 1/24/2024Venrock Healthcare Capital ParMajor ShareholderBuy20,686$12.44$257,333.84 1/22/2024Venrock Healthcare Capital ParMajor ShareholderBuy67,546$12.55$847,702.30 1/18/2024Venrock Healthcare Capital ParMajor ShareholderBuy39,680$12.51$496,396.80 1/16/2024Venrock Healthcare Capital ParMajor ShareholderBuy19,599$12.73$249,495.27 1/11/2024Edward P FeenerInsiderSell22,679$13.03$295,507.37 1/10/2024Venrock Healthcare Capital ParMajor ShareholderBuy47,700$12.67$604,359.00 1/8/2024Edward P FeenerInsiderSell17,221$13.01$224,045.21 1/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy69,184$12.44$860,648.96 1/3/2024Venrock Healthcare Capital ParMajor ShareholderBuy17,605$12.20$214,781.00 12/29/2023Venrock Healthcare Capital ParMajor ShareholderBuy6,013$12.49$75,102.37 12/27/2023Thomas Andrew CrockettCEOSell30,000$12.02$360,600.00 12/27/2023Venrock Healthcare Capital ParMajor ShareholderBuy41,514$11.97$496,922.58 9/11/2023Albert ChaDirectorSell18,000$10.50$189,000.00 8/18/2023Benjamin L PalleikoCFOSell13,067$10.73$140,208.91 8/18/2023Paul K AudhyaInsiderSell8,020$10.73$86,054.60 8/18/2023Thomas Andrew CrockettCEOSell14,876$10.73$159,619.48 5/18/2023Benjamin L PalleikoCFOSell4,037$10.14$40,935.18 5/18/2023Christopher YeaInsiderSell2,604$10.14$26,404.56 5/18/2023Thomas Andrew CrockettCEOSell5,627$10.14$57,057.78 (Data available from 1/1/2013 forward) KALV Insider Trading Activity - Frequently Asked Questions Who is on KalVista Pharmaceuticals's Insider Roster? The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Michael David Smith, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV. What percentage of KalVista Pharmaceuticals stock is owned by insiders? 12.30% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings. Which KalVista Pharmaceuticals insiders have been buying company stock? The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($5,806,280.30). How much insider buying is happening at KalVista Pharmaceuticals? Insiders have purchased a total of 448,522 KALV shares in the last 24 months for a total of $5,806,280.30 bought. Which KalVista Pharmaceuticals insiders have been selling company stock? The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($544,755.63), Christopher Yea ($32,600.72), Edward P Feener ($917,564.74), Paul K Audhya ($112,190.52), and Thomas Andrew Crockett ($1,016,362.46). How much insider selling is happening at KalVista Pharmaceuticals? Insiders have sold a total of 232,618 KalVista Pharmaceuticals shares in the last 24 months for a total of $2,812,474.07 sold. More Insider Trading Tools from MarketBeat Related Companies: PHAT Insider Selling PAHC Insider Selling LYEL Insider Selling LBPH Insider Selling MRNS Insider Selling ALT Insider Selling VTYX Insider Selling AEON Insider Selling PEPG Insider Selling BMEA Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Stocks Insiders Are Buying That Analysts LoveInsider Selling of Amazon Spikes in Q1, but it's Not Time to Sell3 Small Dividend Paying Banks Insiders are Buying3 Stocks Insiders are Buying at New HighsInsider selling at JPM: A Closer Look Amidst Historic CEO Sale This page (NASDAQ:KALV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.